Mabpharm Ltd

02181

Company Profile

  • Business description

    Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.

  • Contact

    Lujia Road East, Koutai Road West
    Block G79, China Medical City
    Taizhou225300
    CHN

    T: +523 80660808

    http://www.mabpharm.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    394

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,697.50139.10-1.57%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,452.6898.49-0.93%
HKSE22,435.24406.38-1.78%
NASDAQ23,879.20550.69-2.25%
Nikkei 22556,967.052,477.16-4.17%
NZX 50 Index14,102.30144.95-1.02%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,597.60132.80-1.52%
SSE Composite Index3,521.4056.22-1.57%

Market Movers